Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Gene expression profiling of tumor-infiltrating CD45+CD8+ cells and CD45- tumor cells of tumor bearing mice treated with metformin or anti-PD-1 Ab or both

ABSTRACT: Gene expression profiling of tumor-infiltrating CD45+CD8+ cells and CD45- tumor cells of tumor bearing mice treated with metformin or anti-PD-1 Ab or both

PROVIDER: PRJNA554254 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR9674410_1.fastq.gz	Fastqsanger.gz
	SRR9674410_2.fastq.gz	Fastqsanger.gz
	SRR9674420_1.fastq.gz	Fastqsanger.gz
	SRR9674420_2.fastq.gz	Fastqsanger.gz
	SRR9674411_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 48

Similar Datasets

Gene expression profiling of tumor-infiltrating CD45+CD8+ cells and CD45- tumor cells of tumor bearing mice treated with metformin or anti-PD-1 Ab or both

Project description:B16 Mouse melanoma cells (MO5) grow in syngeneic C57BL/6 mice. Anti-PD-1 Ab as an Immunecheck point inhibitor and/or metformin were administered on day 7 after tumor inoculation to mice. The tumor growth was decreased by either anti-PD-1 Ab or metformin treatment. Anti- tumor effect was more pronounced by the combination therapy of anti-PD-1 Ab and metformin. The mechanism underlying the superior effect of the combination therapy to mono-therapies were investigated by RNA sequencing of tumor infiltrating CD8+ cells (CD8TILs) and tumor cells. As a result, CD8TILs with the combination therapy was found to express IFNg and GzmB and to activate IRF1/8, STAT1/2, NFkB, TBX21. Moreover, tumor cells were found to activate IRF1/8, STAT1/2, NFkB, indicating that tumor cells sharply responded to IFNg produced from CD8TILs. The IFNg was also found to downregulate metabolism both glycolysis and oxidative phosphorylation (OxPhos) of tumor cells, while it upregulates metabolism of CD8T cells. Collectively, the metabolic competition between CD8TILs and tumor cells was found to shift to the advantage of CD8TILs over tumor cells, resulting in the strong inhibition of tumor growth by the combination therapy of anti-PD-1 Ab and metformin.

2022-07-01 | GSE134191 | GEO

scRNA seq analysis of CD45+ tumor infiltrating cells (TICs) of B16F10 tumor-bearing Trem1+/+ and Trem1-/- mice.

Project description:To gain a global understanding of the impact of TREM1 silencing, we analyzed the CD45+ tumor infiltrating cells (TICs) of B16F10 tumor-bearing Trem1+/+ and Trem1-/- mice. Utilizing the 10x Genomics Chromium Platform, we analyzed approximately 5390 cells per sample with a coverage rate of 15493 genes per cell.

2023-09-27 | E-MTAB-13237 | biostudies-arrayexpress

Expression data from the spleen of tumor bearing mice

Project description:We identify a new cell subset Ter119+CD45- small cells that promotes tumor metastasis in hepatocellular carcinoma (HCC)-bearing mice. We used microarrays to detail the gene expression of Ter119+CD45- cells comparing with CD45- cells in the spleen of hepatocellular carcinoma (HCC)-bearing mice. Ter119+CD45- cells in the spleen of hepatocellular carcinoma (HCC)-bearing mice, being sorted by a MoFlo high-speed cell sorter, were prepared for RNA extraction and hybridization on Affymetrix microarrays. The CD45+ cells from the same tumor bearing mice were prepared as control.

2014-12-19 | E-GEOD-58468 | biostudies-arrayexpress

scRNA seq analysis of CD45+ tumor infiltrating cells (TICs) of B16F10 tumor-bearing Trem1+/+ and Trem1-/- mice.

Project description:scRNA seq analysis of CD45+ tumor infiltrating cells (TICs) of B16F10 tumor-bearing Trem1+/+ and Trem1-/- mice.

| PRJEB64925 | ENA

Expression data from the spleen of tumor bearing mice

2014-12-19 | GSE58468 | GEO

Expression data for tumor-infiltrating CD45+ cells

Project description:Expression data for tumor-infiltrating CD45+ cells

| PRJNA548914 | ENA

Gene expression profile at single cell level of CD45+ tumor-infiltrating immune cells in msothelioma-bearing mice

Project description:Gene expression profile at single cell level of CD45+ tumor-infiltrating immune cells in msothelioma-bearing mice

| PRJNA929282 | ENA

Transcript analysis of CD45+Ter119+CD71+ erythroid-like progenitor cells from tumor-bearing mice

Project description:Transcript analysis of CD45+Ter119+CD71+ erythroid-like progenitor cells from tumor-bearing mice

| PRJNA416659 | ENA

Expression data for tumor-infiltrating CD45+ cells

Project description:Regulatory T (Treg) cells are crucial for immune homeostasis but they also contribute to tumor immune evasion by promoting a suppressive tumor microenvironment (TME). Mice with Treg cell-restricted Neuropilin 1 deficiency show tumor resistance while maintaining peripheral immune homeostasis, thereby providing a controlled system to interrogate the impact of intratumoral Treg cells on the TME. Using this and other genetic models, we showed that Treg cells shaped the transcriptional landscape across multiple tumor-infiltrating immune cell types. Treg cells suppressed CD8+ T cell secretion of interferon- (IFN), which would otherwise block the activation of sterol regulatory element-binding protein 1 (SREBP1)-mediated fatty acid synthesis in immunosuppressive (M2-like) tumor-associated macrophages (TAMs). Thus, Treg cells indirectly but selectively sustained M2-like TAM metabolic fitness, mitochondrial integrity and survival. SREBP1 inhibition augmented the efficacy of immune checkpoint blockade, suggesting that targeting Treg cells or their modulation of lipid metabolism in M2-like TAMs could improve cancer immunotherapy. Microarray gene expression assay was performed to interogate the impact of fragile (Nrp1–/–) Tregs on the gloabal transcriptome oftumor immune infiltrates (CD45+ cells) at various time points over the course of tumor growth.

2019-06-15 | GSE132748 | GEO

CD45+ vs CD45- RCC proteome characterization

Project description:Exploration of proteome differences between CD45+ and CD45- cell types in renal cell carcinoma tumors and normal adjacent tissue patient samples.

2020-10-14 | PXD014370 | Pride

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data